 
 |
|
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Date: July 29, 2010
Client: Anadys Pharmaceuticals, Inc.
Summary: SAN DIEGO, July 29, 2010 -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.
|
|
|
|
 |
|
MedAssurant Data and Analytics Featured in AHIP Presentation on Capitol Hill
Date: July 28, 2010
Client: MedAssurant Inc.
Summary: BOWIE, Md. – July 28, 2010 – MedAssurant Inc., a leading provider of data-driven healthcare solutions, announced that research from a major study by America’s Health Insurance Plans (AHIP) was presented in Washington D.C. today featuring MedAssurant’s data and analytics. The results were presented by AHIP alongside executives from Aetna, Humana, Tufts and United in a session entitled “Reducing Preventable Hospital Readmissions in Medicare.”v
|
|
|
|
 |
|
MorphoSys AG Reports Six Months 2010 Results
Date: July 28, 2010
Client: MorphoSys AG
Summary: MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results for the six months ending June 30, 2010 according to International Financial Reporting Standards (IFRS). Group revenues increased by 15 % to EUR 43.5 million (H1 2009: EUR 37.9 million) and operating profit increased by 26 % to EUR 8.3 million (H1 2009: EUR 6.6 million). Net profit amounted to EUR 5.9 million (H1 2009: EUR 5.0 million), a gain of 18 % over the same period of the previous year. As planned, MorphoSys further increased its investment in proprietary research and development to EUR 11.1 million (H1 2009: EUR 8.5 million). MorphoSys's cash position on June 30, 2010 was EUR 152.1 million (December 31, 2009: EUR 135.1 million). The cash position at balance sheet date still includes the outstanding up-front payment of approx. EUR 10.5 million, which was paid to Xencor in early July. The Company re-confirmed its full year guidance for 2010.
|
|
|
|
 |
|
Therapeutic HIV vaccines show promise
Date: July 27, 2010
Client: Argos Therapeutics
Summary: The world buzzed last week with news that an antiretroviral gel can halve the incidence of HIV infection in women (see Nature doi:10.1038/news.2010.363; 2010).
|
|
|
|
|
|
AbD Serotec Secures Exclusive Worldwide License to Key Diagnostic Antibody
Date: July 26, 2010
Client: MorphoSys AG
Summary: MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its research and diagnostic antibodies unit AbD Serotec has signed an exclusive license agreement with UCL Business PLC (UCLB), the technology development company of University College London (UCL). The agreement provides AbD Serotec with worldwide exclusive access to a potent anti-PTH antibody for commercial use in research and diagnostic applications. The anti-PTH antibody forms the basis of an existing relationship between AbD Serotec and a leading diagnostic company which markets clinical parathyroid hormone assays.
|
|
|
|
 |
|
Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
Date: July 19, 2010
Client: Amira Pharmaceuticals, Inc.
Summary: SAN DIEGO, July 19 /PRNewswire/ -- "Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones."
|
|
|
|
 |
|
Argos Therapeutics' Arcelis™ HIV Immunotherapy Demonstrates Significant Reduction in Viral Load and Delay in Viral Rebound Kinetics in Interim Analysis of Phase 2 Study
Date: July 19, 2010
Client: Argos Therapeutics
Summary: VIENNA, July 19 /PRNewswire/ -- Argos Therapeutics today announced that, in an interim analysis of a Phase 2 trial, its Arcelis immunotherapy targeted at HIV, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption (ARTI) when compared to pre-ART viral loads. The data will be presented in an oral poster presentation session. ART represents a major breakthrough for the management of HIV-infected patients, but is not without side effects and is a life-long commitment. Therapeutic immunotherapies to enhance immune response and control viral replication are needed to limit exposure to ART.
|
|
|
|
|
|
Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
Date: July 13, 2010
Client: Amira Pharmaceuticals, Inc.
Summary: SAN DIEGO, July 13 /PRNewswire/ -- Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, "5-Lipoxygenase Activating Protein (FLAP) Inhibitors," which includes coverage of Amira's AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders.
|
|
|
|
 |
|
Ardea's Gout Therapy The First In 40 Years
Date: July 12, 2010
Client: Ardea Biosciences
Summary: You might think you're in good company with the likes of Galileo, Goethe, Charles Darwin, Sir Isaac Newton, Benjamin Franklin, President Teddy Roosevelt and Karl Marx.
|
|
|
|
 |
|
OrbusNeich's ComboTM Bio-engineered Sirolimus-Eluting Stent Featured in Live Case Demonstration at AICT
Date: July 2, 2010
Client: OrbusNeich
Summary: SINGAPORE, July 2, 2010 – OrbusNeich announced that their next generation Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) was featured today in a live case demonstration at the 6th Asian Interventional Cardiovascular Therapeutics 2010 (AICT) in Singapore.
|
|
|
|
 |
|
Arena in deal with Eisai for US weight drug rights
Date: July 1, 2010
Client: Arena Pharmaceuticals, Inc.
Summary: NEW YORK, July 1 (Reuters) - Arena Pharmaceuticals Inc(ARNA.O) said on Thursday it signed a partnership deal with Japan's Eisai Co (4523.T) to sell its closely watched obesity drug lorcaserin in the United States once it gains approval.
|
|
|
|
 |
|
Eisai to Market Arena Pharmaceuticals' Lorcaserin for Obesity and Weight Management in U.S. Following FDA Approval
Date: July 1, 2010
Client: Arena Pharmaceuticals, Inc.
Summary: SAN DIEGO, July 1, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.
|
|
|
|
|
